Bausch Health Companies Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Tom Appio

Chief Executive Officer (CEO)

US$15.9m

Compensación total

Porcentaje del salario del CEO	7.4%
Permanencia del CEO	2yrs
Participación del CEO	0.1%
Permanencia media de la dirección	2.2yrs
Promedio de permanencia en la Junta Directiva	7.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Tom Appio en comparación con los beneficios de Bausch Health Companies?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$455m
Dec 31 2023	US$16m	US$1m	-US$592m
Sep 30 2023	n/a	n/a	-US$963m
Jun 30 2023	n/a	n/a	-US$186m
Mar 31 2023	n/a	n/a	-US$357m
Dec 31 2022	US$13m	US$1m	-US$225m
Sep 30 2022	n/a	n/a	US$254m
Jun 30 2022	n/a	n/a	US$43m
Mar 31 2022	n/a	n/a	-US$407m
Dec 31 2021	US$10m	US$854k	-US$948m
Sep 30 2021	n/a	n/a	-US$1b
Jun 30 2021	n/a	n/a	-US$1b
Mar 31 2021	n/a	n/a	-US$1b
Dec 31 2020	US$4m	US$775k	-US$560m
Sep 30 2020	n/a	n/a	-US$2b
Jun 30 2020	n/a	n/a	-US$2b
Mar 31 2020	n/a	n/a	-US$2b
Dec 31 2019	US$4m	US$769k	-US$2b
Sep 30 2019	n/a	n/a	-US$616m
Jun 30 2019	n/a	n/a	-US$917m
Mar 31 2019	n/a	n/a	-US$2b
Dec 31 2018	US$4m	US$730k	-US$4b
Sep 30 2018	n/a	n/a	-US$3b
Jun 30 2018	n/a	n/a	-US$2b
Mar 31 2018	n/a	n/a	-US$805m
Dec 31 2017	US$3m	US$650k	US$2b

Compensación vs. Mercado: La compensación total de Tom($USD15.88M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD2.47M).

Compensación vs. Ingresos: La compensación de Tom ha aumentado mientras la empresa no es rentable.

CEO

Tom Appio (61 yo)

2yrs

Permanencia

US$15,878,578

Compensación

Mr. Thomas J. Appio, also known as Tom, serves as the Chief Executive Officer & Director at Bausch Health Companies Inc. and served as Chief Executive Officer of Pharma Business and served as President & C...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Thomas Appio	CEO & Director	2yrs	US$15.88m	0.11% $ 2.6m
John Barresi	Senior VP	1.9yrs	US$1.40m	0.0045% $ 103.2k
Seana Carson	Executive VP & General Counsel	2yrs	US$3.16m	0.023% $ 515.5k
Mirza Dautbegovic	Senior VP & COO	2.3yrs	sin datos	0.024% $ 555.9k
Josh Coyle	Senior Vice President of Sales & Salix	1.3yrs	sin datos	sin datos
Kathleen Fitzpatrick	Senior VP & Chief HR Officer	2.3yrs	sin datos	sin datos
Tage Ramakrishna	Chief Medical Officer and President of R&D	no data	sin datos	sin datos
Jeff Hartness	Executive VP of Market Access	3.9yrs	sin datos	sin datos
Graham Jackson	Senior VP & Chief Quality Officer	2.3yrs	sin datos	sin datos
Cees Heiman	Senior Vice President of Europe & Canada	2.3yrs	sin datos	sin datos
Donald Pearl	Senior Vice President of Ortho Dermatologics	no data	sin datos	sin datos
Jiny Kim	Senior Vice President of Solta Medical	1.3yrs	sin datos	sin datos

2.2yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de BVF se considera experimentado (2.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Thomas Appio	CEO & Director	2yrs	US$15.88m	0.11% $ 2.6m
John Paulson	Independent Chairman	1.9yrs	US$812.50k	0.000060% $ 1.4k
Robert Power	Independent Director	15.8yrs	US$389.55k	0.0018% $ 41.1k
H. Fibiger	Chairman of External Advisory Board	no data	US$2.00m	sin datos
Sarah Kavanagh	Independent Director	7.8yrs	US$718.28k	0% $ 0
Robert Lenox	Member of the External Advisory Board	15.2yrs	sin datos	sin datos
Kathleen Clarence-Smith	Member of the External Advisory Board	15.2yrs	sin datos	sin datos
Karoly Nikolich	Member of the External Advisory Board	15.2yrs	sin datos	sin datos
Brett Icahn	Independent Director	3.2yrs	US$691.72k	0.00020% $ 4.6k
Amy Wechsler	Independent Director	7.9yrs	US$377.50k	0.011% $ 262.4k
Steven Miller	Independent Director	3.2yrs	US$381.31k	0.031% $ 702.7k
Christian Garcia	Independent Director	no data	sin datos	sin datos

7.8yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de BVF se considera experimentada (7.8 años de antigüedad promedio).

Bausch Health Companies Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Bausch Health Companies Inc. Approves Directorate Appointments

Insufficient new directors

Bausch Health Companies Inc., Annual General Meeting, May 14, 2024

Bausch Health Companies Inc. Announces Executive Changes

Insider recently sold €708k worth of stock

Insufficient new directors

Recent updates

Bausch Health Companies Inc. Approves Directorate Appointments

First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.55 loss in 1Q 2023)

Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health Companies Inc. to Report Q1, 2024 Results on May 02, 2024

Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults

Insufficient new directors

Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma

Full year 2023 earnings released: US$1.62 loss per share (vs US$0.62 loss in FY 2022)

Bausch Health Companies Inc., Annual General Meeting, May 14, 2024

Bausch Health Companies Inc. to Report Q4, 2023 Results on Feb 22, 2024

Bausch Health Companies Inc. Announces the U.S. Launch of CABTREO Topical Gel

Bausch Health Companies Inc. and Salix Pharmaceuticals Ltd. Provides Update on Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute

Bausch Health Companies Inc. Announces Positive Topline Results from Global Phase 2 Study Evaluating Amiselimod (An S1p Antagonist) to Treat Ulcerative Colitis

No longer forecast to breakeven

Bausch Health, Canada Announces DUOBRII Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec's Public Drug Plan

No longer forecast to breakeven

Third quarter 2023 earnings released: US$1.04 loss per share (vs US$1.10 profit in 3Q 2022)

FDA Approves Bausch Health Companies Inc. and Its Dermatology Business, Ortho Dermatologics's Cabtreo Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older

Bausch Health Companies Inc. to Report Q3, 2023 Results on Nov 02, 2023

Bausch Health Companies Inc. Announces Executive Changes

Bausch Health Companies Inc. Announces New Treatment PrUCERIS (Budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Bausch Health Companies Inc. Raises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.072 (vs US$0.40 loss in 2Q 2022)

Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of Bausch Health Companies Inc

Bausch Health Companies Inc. to Report Q2, 2023 Results on Aug 03, 2023

New major risk - Financial position

No longer forecast to breakeven

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.56 loss per share (vs US$0.19 loss in 1Q 2022)

Bausch Health Companies Inc. Provides Consolidated Earnings Guidance for the Full Year 2023

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released: US$0.62 loss per share (vs US$2.64 loss in FY 2021)

Investor sentiment improves as stock rises 23%

Bausch Health Companies Inc. to Report Q4, 2022 Results on Feb 23, 2023

Investor sentiment improved over the past week

Bausch Health Companies Inc. Announces Availability of ARAZLOTM

Third quarter 2022 earnings released: EPS: US$1.10 (vs US$0.52 in 3Q 2021)

Bausch Health Companies Inc. Revises Consolidated Earnings Guidance for the Full Year 2022

Bausch Health Companies Inc. to Report Q3, 2022 Results on Nov 03, 2022

Bausch Health Companies Inc. and Glenmark Specialty S.A. Announce the Approval of RYALTRIS® in Canada

Insider recently sold €708k worth of stock

Bausch Health Companies Inc.(TSX:BHC) dropped from FTSE All-World Index (USD)

Investor sentiment improved over the past week

Bausch Health Companies Inc. Responds to Norwich Pharmaceuticals Tentative FDA Approval for 200 mg Rifaximin

Investor sentiment improved over the past week

Bausch Health Companies Inc. to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit

Second quarter 2022 earnings released

Bausch Health Companies Inc. Announces Unaudited Impairment Results for the Quarter Ended June 30, 2022

Insufficient new directors

Bausch Health Companies Inc. to Report Q2, 2022 Results on Aug 09, 2022

Insufficient new directors

Bausch Health Companies Inc. Announces Updates to Its Board of Directors

Bausch Health Companies Inc. Appoints John S. Barresi as the Company’s Senior Vice President, Controller and Chief Accounting Officer

Bausch Health Companies Inc. Provides Revenue Guidance for the Year Full Year 2022

Bausch Health Companies Inc. Announces Management Changes

Bausch Health Companies Inc. to Report Q1, 2022 Results on May 10, 2022

Bausch Health Companies Inc., Annual General Meeting, Jun 14, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Bausch Health Companies Inc. Provides Earnings Guidance for the Year 2022

Bausch Health, Canada Announces Availability through Pharmacies Across Canada of its New Prescription Treatment TRULANCE

Bausch Health Companies Inc. to Report Q4, 2021 Results on Feb 23, 2022

Insufficient new directors

Bausch Health Companies Inc. has filed an IPO.

Bausch Health Companies Inc. Announces New Post-Hoc Analysis of Pooled Results on the Safety and Efficacy of A Single Dose of Relistor Injection

Insider recently bought €1.3m worth of stock

Third quarter 2021 earnings released: EPS US$0.52 (vs US$0.20 in 3Q 2020)

Forecast to breakeven in 2022